Sutro Biopharma shares are trading higher after Oppenheimer maintained its Outperform rating and $10 price target on the stock. The company recently reported 2023 financial results.

Sutro Biopharma +1.47% Post

Sutro Biopharma

STRO

4.14

4.14

+1.47%

0.00% Post

Sutro Biopharma shares are trading higher after Oppenheimer maintained its Outperform rating and $10 price target on the stock. The company recently reported 2023 financial results.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via